Robbie Stephens Cuts Chiron Rating

Analyst Michael King is disappointed with the FDA's delay in approval for the biotech firm's blood testing system

Robertson Stephens downgraded Chiron (CHIR ) to market underperform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.